Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pim Kinase Inhibitor Enhances FLT3 Inhibitor Efficacy through GSK-3β Activation and GSK-3β-Mediated Proteasomal Degradation of c-Myc

Jonelle K. Lee, Mario Scarpa, Aditi Chatterjee, Moaath Mustafa Ali, Prerna Singh, Shivani Kapoor, Rossana Trotta, Maria R. Baer

Blood (2021) 138 (Supplement 1): 1163.

https://doi.org/10.1182/blood-2021-151737

Published: 2021

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

Mario Scarpa, PhD, Shivani Kapoor, MS, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2018) 132 (Supplement 1): 3951.

https://doi.org/10.1182/blood-2018-99-117609

Published: 2018

Journal Articles

Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs

Kshama A. Doshi, PhD, Shivani Kapoor, MS, Ying Zou, MD PhD, Xiang Li, PhD, Mario Scarpa, MS, Nidal Muvarak, PhD, Pratik Nagaria, PhD, Olga Goloubeva, PhD MSc, Adriana E. Tron, PhD, Charles J. Bieberich, PhD, Feyruz V. Rassool, BSc, PhD, Maria R. Baer, MD

Blood (2017) 130 (Supplement 1): 1243.

https://doi.org/10.1182/blood.V130.Suppl_1.1243.1243

Published: 2017

Journal Articles

Combined Treatment with JQ1 and Curcumin Synergically Modulates Apoptosis, Cell Cycle Features, Micrornas and Gene Expression in High-Risk Pediatric Acute Myeloid Leukemia (AML)

Patrizia Vitullo, PhD, Pier Paolo Leoncini, PhD, Valeria Tocco, Angela Pitisci, Daniela Montagna, Pigazzi Martina, PhD, Paolo Fadda, Pharm D, Dario Veneziano, PhD, Giovanni Nigita, PhD, Mario Scarpa, MS, Katia D'Ovidio, Rossella Rota, PhD, Alice Bertaina, MD PhD

Blood (2017) 130 (Supplement 1): 2698.

https://doi.org/10.1182/blood.V130.Suppl_1.2698.2698

Published: 2017

NARROW

Pim Kinase Inhibitor Enhances FLT3 Inhibitor Efficacy through GSK-3β Activation and GSK-3β-Mediated Proteasomal Degradation of c-Myc

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs

Combined Treatment with JQ1 and Curcumin Synergically Modulates Apoptosis, Cell Cycle Features, Micrornas and Gene Expression in High-Risk Pediatric Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Pim Kinase Inhibitor Enhances FLT3 Inhibitor Efficacy through GSK-3β Activation and GSK-3β-Mediated Proteasomal Degradation of c-Myc

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs

Combined Treatment with JQ1 and Curcumin Synergically Modulates Apoptosis, Cell Cycle Features, Micrornas and Gene Expression in High-Risk Pediatric Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only